HC Wainwright Issues Negative Estimate for Innoviva Earnings

Innoviva, Inc. (NASDAQ:INVA) – Equities research analysts at HC Wainwright dropped their Q4 2025 EPS estimates for shares of Innoviva in a note issued to investors on Monday, November 10th. HC Wainwright analyst R. Selvaraju now forecasts that the biotechnology company will post earnings of $0.48 per share for the quarter, down from their previous estimate of $0.54. HC Wainwright currently has a “Buy” rating and a $45.00 target price on the stock. The consensus estimate for Innoviva’s current full-year earnings is $0.33 per share. HC Wainwright also issued estimates for Innoviva’s Q1 2026 earnings at $0.45 EPS, Q3 2026 earnings at $0.57 EPS and FY2026 earnings at $2.23 EPS.

INVA has been the subject of a number of other research reports. Weiss Ratings raised Innoviva from a “hold (c)” rating to a “buy (b-)” rating in a report on Friday. Oppenheimer began coverage on Innoviva in a research note on Monday, August 11th. They set an “outperform” rating and a $45.00 target price for the company. Wall Street Zen upgraded shares of Innoviva from a “buy” rating to a “strong-buy” rating in a research note on Saturday, October 25th. Cantor Fitzgerald lifted their price target on shares of Innoviva from $29.00 to $31.00 and gave the company an “overweight” rating in a report on Thursday, November 6th. Finally, Zacks Research downgraded shares of Innoviva from a “strong-buy” rating to a “hold” rating in a research note on Thursday, November 6th. Five analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Innoviva currently has an average rating of “Moderate Buy” and an average price target of $38.60.

Innoviva Stock Up 4.9%

Shares of INVA opened at $21.90 on Wednesday. The firm has a 50 day simple moving average of $18.66 and a two-hundred day simple moving average of $19.29. The company has a debt-to-equity ratio of 0.36, a current ratio of 2.64 and a quick ratio of 2.44. Innoviva has a one year low of $16.52 and a one year high of $22.00. The company has a market cap of $1.38 billion, a P/E ratio of 70.65 and a beta of 0.42.

Innoviva (NASDAQ:INVA) last issued its quarterly earnings results on Wednesday, November 5th. The biotechnology company reported $1.08 earnings per share for the quarter, topping analysts’ consensus estimates of $0.46 by $0.62. The company had revenue of $107.80 million during the quarter, compared to the consensus estimate of $91.31 million. Innoviva had a net margin of 10.44% and a return on equity of 18.67%.

Institutional Investors Weigh In On Innoviva

A number of institutional investors have recently added to or reduced their stakes in INVA. Principal Financial Group Inc. increased its position in Innoviva by 2.6% in the 1st quarter. Principal Financial Group Inc. now owns 305,476 shares of the biotechnology company’s stock valued at $5,538,000 after acquiring an additional 7,700 shares during the period. Victory Capital Management Inc. grew its stake in shares of Innoviva by 132.4% in the first quarter. Victory Capital Management Inc. now owns 412,281 shares of the biotechnology company’s stock worth $7,475,000 after purchasing an additional 234,898 shares during the last quarter. Bailard Inc. acquired a new stake in Innoviva in the first quarter valued at $189,000. Denali Advisors LLC raised its position in Innoviva by 6.3% during the 1st quarter. Denali Advisors LLC now owns 376,606 shares of the biotechnology company’s stock worth $6,828,000 after purchasing an additional 22,282 shares during the last quarter. Finally, Universal Beteiligungs und Servicegesellschaft mbH bought a new position in Innoviva during the 1st quarter worth $627,000. 99.12% of the stock is owned by institutional investors.

About Innoviva

Innoviva, Inc engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company’s products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.